Oralis (887907)

  https://cordis.europa.eu/project/id/887907

  Horizon 2020 (2014-2020)

  Oralis, The first oral human insulin treatment for Type 2 Diabetes Mellitus

  SME instrument (EIC-SMEInst-2018-2020)

  pharmaceutical drugs  ·  proteins  ·  diabetes  ·  continuous glucose monitors

  2019-12-01 Start Date (YY-MM-DD)

  2020-03-31 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Type 2 Diabetes Mellitus (T2DM) affects 415M people globally, 49M of them within Europe. Caring for these individuals costs Europe €181M billion annually. However, more needs to be done as T2DM and its related co-morbidities claim hundreds of thousands of lives each year in the region. The early control of blood glucose levels (BGL) is the key to the prevention of the disease, and longer lifespans with better prognosis and higher quality of life for T2DM patients. The last century has seen considerable development in T2DM treatment, but the eventual solution to control BGL for many patients are multiple daily insulin injections. This has created a huge global market to be worth €49 billion (est. 2020). The pain, social stigma, and burden associated with injecting insulin contribute to a non-adherence to treatment that has been estimated to be as high as 61%, at a cost 9,649€ per patient per year. Oramed Pharmaceuticals (Oramed) will transform this paradigm with its POD™ technology. It protects protein therapies like insulin from the harsh conditions in the gastrointestinal tract, allowing then to be taken orally. This opens a way into oral insulin treatment to overcome many of the issues contributing to non-adherence of injected insulin treatment in T2DM patients. Using POD™ technology Oramed has produced the first oral insulin and demonstrated its efficacy in Phase II clinical trials with >300 patients and >5000 doses. We have proven oralis capability to deliver to the liver bioavailable insulin at sufficient concentration to produce significant glucose control in all glycaemic parameters in T2DM patients. Through the SME instrument Oramed will finalise the Phase III clinical trial to confirm the efficacy of oralis for glycaemic control in T2DM patients. We have already reach commercial agreements to commercialise oralis. Our estimation is to generate a similar revenue creation and market share as the newest injectable insulin options of €1.7 bn in 5 years.

  Complicit Organisations

1 Israeli organisation participates in Oralis.